Can Slow-Growing Prostate Cancer Become Aggressive?

Being told you have slow-growing prostate cancer can bring mixed emotions. You might feel relieved that immediate treatment isn’t needed, but still worry about whether the cancer could change or become harder to treat over time.

The reassuring part is that many low-risk prostate cancers stay stable for years and may never cause harm. Still, some can show signs of progression, which is why careful monitoring is important rather than leaving it unchecked.

If active surveillance is suitable, your specialist will recommend a structured monitoring plan that may include regular PSA tests, digital rectal examinations, MRI scans and repeat biopsies when clinically appropriate. If tests show clinically important progression, treatment can often begin while a curative approach remains possible.

What Does Slow-Growing Prostate Cancer Mean?

Slow-growing prostate cancer is an informal description rather than a formal medical risk category. Your specialist will assess your cancer using factors such as your PSA level, Grade Group, clinical stage, MRI findings and biopsy results, which may be combined into a Cambridge Prognostic Group.

Slow-growing prostate cancer means your cancer is unlikely to grow or spread quickly based on what’s known at diagnosis. Your medical team looks at things like your PSA level, biopsy Grade Group, MRI findings, clinical stage and how much cancer is in your biopsy samples to assess this.

Even though it’s called low risk, it is still cancer. The difference is that it’s expected to behave less aggressively than higher-grade or more advanced types.

In many cases, this type of cancer can stay confined to the prostate for years. For you, that may mean it never causes symptoms or affects your life expectancy, which is why immediate treatment isn’t always necessary.

Can a Slow-Growing Cancer Become Aggressive?

Yes, prostate cancer that initially appears slow-growing can show biological progression over time, although some apparent changes reflect more accurate testing detecting higher-grade disease that was already present. Possible signs include a higher Grade Group on repeat biopsy, an increase in the amount of cancer detected, more suspicious MRI findings or evidence that the tumour is extending beyond the prostate.

That said, progression is not inevitable. Many men remain on active surveillance for years without needing treatment.

Active surveillance is designed to identify clinically important changes while treatment with curative intent may still be possible.

Progression and Reclassification Are Not Always the Same

If your later tests show a higher-grade cancer, it’s natural to feel like things have suddenly worsened. In some cases, the cancer may have progressed, while in others, the higher-grade area may already have been present but was not detected during the first biopsy.

This happens because a biopsy only samples parts of your prostate, not the whole gland. A later MRI or repeat biopsy may identify an area that was previously too small, difficult to sample or not detected during the initial assessment.

A higher-grade result may therefore represent reclassification of cancer that was already present rather than a recent change in the behaviour of the tumour. This is one reason regular monitoring is important. It allows your team to identify meaningful changes while treatment with curative intent may still be appropriate.

Why the Grade Group Matters

Your Grade Group describes how the cancer cells look under a microscope. For you, a lower Grade Group usually means the cancer is less aggressive, while a higher Grade Group suggests cells that are more abnormal and more likely to grow or spread.

If a repeat biopsy shows a higher Grade Group, this is known as upgrading. It may lead your multidisciplinary team to reconsider active surveillance, although the decision should also take account of the extent of the higher-grade disease, MRI findings, PSA pattern, general health and personal preferences.

That decision isn’t based on one factor alone. Your doctor will also consider your MRI results, PSA trends, how much cancer is present, your overall health and your personal preferences before recommending the next step.

Cancer Volume Can Change Even Without Upgrading

The grade of your cancer is important, but it’s not the only factor that matters. The cancer may remain within the same Grade Group but appear in more biopsy samples, involve a greater proportion of individual samples or form a larger or more concerning area on MRI.

An apparent increase in cancer volume may reflect genuine growth, but it can also result from differences in how the prostate was sampled during separate biopsies.

An increase in cancer volume can suggest that the disease is becoming more significant, even without a change in grade. This is why your monitoring looks at more than just one measurement.

Your medical team will assess these changes alongside where the tumour is located and whether there are any signs of it extending towards or beyond the prostate. This helps your team decide whether continuing surveillance or moving to treatment is the most suitable option for you.

Why Active Surveillance Is Offered

Current NICE guidance recommends offering active surveillance to people with CPG 1 localised prostate cancer. For CPG 2 disease, active surveillance is one of the options alongside radical prostatectomy and radical radiotherapy when radical treatment is suitable. For CPG 3 disease, radical prostatectomy or radical radiotherapy should be offered, while active surveillance may be considered if the person chooses not to have immediate radical treatment.

NICE advises that active surveillance should not be offered for CPG 4 or CPG 5 localised or locally advanced prostate cancer.

Key Points About Active Surveillance

Aspect	What It Means	Potential Benefits	Important Considerations
Suitable cancer types	Usually offered for low-risk and selected intermediate-risk localised prostate cancer	Avoids unnecessary immediate treatment	Active surveillance is not recommended for CPG 4 or CPG 5 disease, and suitability must be assessed individually.
Monitoring approach	Regular PSA tests, clinical reviews and digital rectal examinations, with multiparametric MRI at 12 to 18 months and further MRI or repeat biopsy if PSA or clinical findings cause concern. Local surveillance protocols may differ.	May help identify clinically important changes during follow-up	Requires ongoing follow-up appointments
Delaying treatment	Further assessment and treatment can be considered if tests show clinically important progression or if continuing surveillance is no longer acceptable to the patient.	Helps reduce exposure to side effects	Some men may need treatment later
Avoiding side effects	May delay or avoid urinary, sexual and bowel side effects associated with radical treatment.	Can help maintain quality of life	Surveillance can still involve anxiety, repeated tests and biopsy-related side effects.
CPG risk groups	NICE recommends active surveillance for CPG 1, includes it as an option for CPG 2 and allows consideration for some people with CPG 3	Provides an alternative to immediate radical treatment when clinically appropriate	Active surveillance should not be offered for CPG 4 or CPG 5 disease
Shared decision-making	Your preferences and health goals are considered alongside clinical factors	Helps you choose an approach that suits your priorities	Regular discussions with your specialist are important

UK Guidance Note

Current NICE guidance recommends active surveillance for suitable CPG 1 prostate cancer and includes it as a treatment option for CPG 2 disease. It may also be considered for some people with CPG 3 disease who choose not to have immediate radical treatment. It should not be offered for CPG 4 or CPG 5 disease.

The current NICE surveillance protocol includes PSA testing every three to four months during the first year and every six months thereafter. It also includes a digital rectal examination at 12 months and annually after that, together with multiparametric MRI at 12 to 18 months. Local protocols may differ, and NICE is reviewing its active-surveillance recommendations.

Active Surveillance Is Not Doing Nothing

It can feel unsettling to know you have cancer but not start treatment straight away. For you, active surveillance is not about ignoring the condition but following a structured plan with regular checks and clear steps if anything changes.

The aim is to monitor the cancer while treatment with curative intent remains a suitable option if clinically important progression develops.

By completing tests at recommended intervals, your clinical team can assess patterns over time and investigate concerning changes promptly. This may allow clinically important changes to be investigated before symptoms develop or the cancer becomes more difficult to treat.

Active Surveillance and Watchful Waiting Are Different

Active surveillance and watchful waiting are not the same, even though they can sound similar. For you, active surveillance is usually offered when the cancer is still localised and treatment with the aim of cure would remain an option if the cancer shows signs of progression.

Active surveillance involves a structured plan of PSA testing, clinical review, digital rectal examination, MRI and repeat biopsy according to the surveillance protocol and any concerning changes. The goal is to monitor the cancer closely and act early if there are meaningful changes.

Watchful waiting is a less intensive approach and is often considered when other health factors or personal preference make curative treatment less suitable. In this situation, treatment is usually introduced to manage symptoms rather than cure the cancer, so it is important to understand which approach you are following.

How PSA Testing Helps Monitor Change

PSA testing is one of the main ways your cancer is monitored during active surveillance. For you, it is not just about a single result, but how your PSA levels change over time.

Your medical team looks at patterns such as whether the PSA is rising steadily, how quickly it is increasing and how it relates to your prostate size. This helps build a clearer picture of whether the cancer is remaining stable or showing signs of activity.

Current NICE guidance recommends PSA testing every three to four months during the first year of active surveillance and every six months from the second year onwards. Your hospital may use a different schedule based on your clinical circumstances and local protocol.

A Rising PSA Does Not Automatically Mean Aggressive Cancer

A rise in your PSA level does not always mean your cancer is becoming more aggressive. PSA can increase for several reasons, including prostate enlargement, inflammation or infection.

Because of this, your specialist will not usually rely on a single PSA result. For you, the pattern over time is much more important than one isolated reading.

If your PSA pattern is concerning, your team may repeat the blood test, check for other possible causes and arrange further assessment with MRI and, when appropriate, another biopsy. A rising PSA alone does not usually provide enough evidence to confirm progression or justify a change to active treatment.

PSA Velocity and PSA Density Add Context

PSA velocity looks at how quickly your PSA level changes over time, while PSA density compares your PSA level to the size of your prostate. These measurements provide additional context and may help your team decide whether MRI or biopsy reassessment is needed.

On their own, these measures do not provide a diagnosis. They are used alongside other information to build a clearer picture of your situation.

Guidance recommends monitoring PSA patterns during active surveillance and reassessing with MRI or repeat biopsy if there are concerning changes. This helps ensure that any decisions about your care are based on a full and accurate assessment.

MRI Can Show Whether a Lesion Is Changing

Multiparametric MRI provides detailed images of your prostate and can highlight areas that may be concerning. For you, it helps your team see whether a known lesion has grown, developed more suspicious features or is extending towards nearby structures.

This type of imaging adds important information that cannot be obtained from PSA testing alone. It allows your doctors to monitor visible changes in the cancer over time.

Guidance recommends having an MRI when you start active surveillance if you have not already had one. Current NICE guidance recommends multiparametric MRI at 12 to 18 months after active surveillance begins, with further MRI or biopsy reassessment if PSA or clinical findings cause concern.

The exact timing may vary because hospitals use different surveillance protocols and NICE is reviewing its current active-surveillance recommendations.

MRI Results Need to Be Interpreted Carefully

An MRI can highlight areas that look suspicious, but it does not examine cancer cells directly. For you, this means a scan may appear stable even if small changes are present, or it may look concerning due to inflammation or benign tissue.

Because of this, your specialist will not rely on MRI results alone. Your scan is interpreted alongside PSA trends, biopsy findings and previous imaging to build a more complete picture.

If results do not fully match, further review or a targeted biopsy may be recommended. This helps ensure that decisions about your care are based on the most accurate information available.

Why a Repeat Biopsy May Be Needed

A repeat biopsy allows your medical team to reassess your cancer more directly. It can show whether a higher Grade Group or a greater amount of cancer is now detected, although this may represent either biological progression or disease that was not identified previously.

A repeat biopsy can target suspicious areas identified on MRI and may also include systematic samples from other parts of the prostate.

Not all surveillance programmes schedule biopsies at fixed times. In some cases, PSA results and MRI findings guide when another biopsy is needed, but it remains an important test when there is uncertainty or concern about change.

The Role of the Prostate Examination

During a digital rectal examination, your clinician feels the back surface of the prostate through the rectum to check for changes in size, firmness or shape. For you, this can help identify any new firmness, irregularity or change that may need further investigation.

This examination complements PSA testing and imaging by providing additional clinical information that may indicate a need for further assessment.

Current NICE guidance recommends a digital rectal examination at 12 months and every 12 months thereafter during active surveillance. Your follow-up schedule may vary depending on your risk level and how your local care pathway is structured.

What Counts as a Sign of Progression

Progression is not based on a single number or test result. For you, it is assessed by looking at the overall pattern across PSA changes, MRI findings and biopsy results.

Possible signs include a higher Grade Group on repeat biopsy, an increase in the extent of cancer found in biopsy samples, more concerning MRI appearances or evidence that the tumour has extended beyond the prostate.

A concerning PSA pattern may trigger further investigation, but PSA change alone does not confirm biological progression.

Your multidisciplinary team will review all of this information together to decide whether there is true progression. If the combined findings show clinically important progression, your multidisciplinary team may recommend treatment after discussing the expected benefits, side effects and alternatives with you.

Symptoms Are Not the Best Early Warning System

Early localised prostate cancer often causes no symptoms, even if it begins to change. For you, this means waiting for issues such as urinary problems, pain or visible blood is not a reliable way to detect progression.

Regular monitoring tests are a more effective way to identify changes early. These are designed to detect signs of progression before symptoms develop.

Changes in urination are often caused by non-cancerous conditions such as benign prostate enlargement. Even so, you should report any new or persistent symptoms so your medical team can decide if further assessment is needed.

When New Symptoms Need Prompt Attention

You should contact your clinical team if you notice new symptoms that concern you, especially if they are persistent or getting worse. Contact your GP or prostate cancer team if you develop persistent bone or back pain, visible blood in your urine, worsening urinary symptoms, unexplained weight loss or fatigue that does not improve.

Call 999 or attend A&E immediately if back pain is accompanied by new weakness or numbness in your legs, difficulty walking or new loss of bladder or bowel control. These may be signs of metastatic spinal cord compression, which is an oncological emergency. Do not wait for your next routine appointment.

These symptoms are not used on their own to diagnose cancer progression. However, they are important signals that your medical team may need to investigate further.

Active surveillance is designed to detect early changes through regular testing. Any new symptoms are considered alongside your PSA results, MRI findings and other assessments to give a complete and accurate picture.

When Treatment May Become Necessary

Treatment may be recommended when the balance of risk changes and the cancer is more likely to cause harm if left untreated. For you, this could include a higher biopsy grade, increasing tumour volume, more concerning MRI findings or a combination of changes over time.

These findings suggest that the cancer may no longer be safely monitored with surveillance alone. At that point, your team may discuss treatment with curative intent when it remains clinically appropriate.

The decision is still made with you, not for you. Your age, overall health, priorities around quality of life and your feelings about continued monitoring all play an important role in choosing the next step.

Surgery After Active Surveillance

Radical prostatectomy removes the prostate and seminal vesicles and is an established treatment with curative intent for suitable localised prostate cancer. For you, surgery may be discussed if monitoring shows progression and your cancer and overall health make an operation a suitable option.

The potential benefits of surgery need to be balanced against possible risks. These can include urinary incontinence, erectile dysfunction and other complications related to the procedure.

The timing and type of surgery will depend on the specifics of your cancer, including its location and extent. Progression does not automatically mean that every surgical approach will be appropriate, so your treatment plan will be tailored to your situation.

Radiotherapy After Active Surveillance

Radiotherapy is another established treatment that may be offered with curative intent for suitable localised prostate cancer. For you, this may involve external beam radiotherapy or brachytherapy, and in some cases hormone therapy may be added depending on the level of risk.

This approach avoids surgery, but it comes with its own potential side effects. These can include urinary, bowel and sexual changes that vary from person to person.

Your oncologist will guide you on the most suitable option based on the grade, stage and location of your cancer, as well as your overall health and any previous treatments.

Is Focal Therapy an Option if the Cancer Changes?

Focal therapy treats a selected area of the prostate rather than the whole gland. Techniques include high-intensity focused ultrasound and focal cryoablation. It is not a routine standard replacement for surgery or radiotherapy when active surveillance ends. It may be considered for carefully selected patients in specialist centres, but NICE states that evidence about how effectively these procedures control cancer is limited.

Focal therapy is not an automatic next step when active surveillance ends. Prostate cancer is often multifocal, which means cancer can be present in more than one part of the gland. Treatment also requires continued PSA testing, MRI scans and sometimes further biopsies because cancer may remain, return or develop in another area.

NICE considers the safety evidence for focal high-intensity focused ultrasound adequate but states that evidence about its effectiveness is limited. The procedure should therefore be used only with special arrangements for clinical governance, consent and audit or research.

Your Age and General Health Can Change the Plan

A decision to remain on active surveillance can be revisited over time, even if the cancer itself has changed very little. For you, changes in your general health or life expectancy may influence whether certain treatments remain suitable.

Your suitability for surgery, radiotherapy or hormone therapy may change as you get older or develop other medical conditions. This means your care plan may need to be adjusted to reflect your current situation rather than past assumptions.

For some people, active surveillance continues because curative treatment is still appropriate if needed. For others, the focus may gradually move towards watchful waiting if overall health becomes a more important factor than the cancer risk.

Family History and Inherited Risk May Be Relevant

Family history and inherited genetic variants may contribute to your overall risk assessment, but they do not by themselves determine whether active surveillance is suitable. Their relevance depends on the cancers present in your family, the ages at which relatives were diagnosed and whether a specific inherited variant has been identified.

• Family history: Having relatives with prostate, breast, ovarian or pancreatic cancer may affect how your personal risk is evaluated
• Inherited mutations: Some inherited pathogenic variants, particularly in BRCA2, are associated with an increased risk of prostate cancer, including more aggressive forms of the disease.
• Risk assessment: Family history and genetics are considered alongside other factors when planning your care
• Surveillance discussions: Relevant genetic findings may be considered alongside your Grade Group, PSA results, MRI findings, age and general health
• Genetic counselling: Further assessment or testing may be recommended if it could provide useful information for your treatment plan

Tell your specialist about prostate, breast, ovarian and pancreatic cancers in close relatives. Genetic counselling or testing may be considered when the family pattern suggests an inherited cancer-risk variant.

Can Lifestyle Stop Prostate Cancer Progressing?

No diet, supplement or exercise plan has been shown to guarantee that slow-growing prostate cancer will remain stable or harmless. For you, it is important to be cautious of claims that suggest lifestyle changes can replace monitoring or remove the need for medical treatment.

Healthy habits can still play a valuable role in your overall wellbeing. Eating a balanced diet, staying physically active, not smoking and maintaining a healthy weight can support your heart, bones and general fitness.

While the direct effect on cancer growth is uncertain, these lifestyle choices may help you feel better day to day and prepare your body if treatment becomes necessary later.

Anxiety Can Affect Your Treatment Decision

Living with untreated cancer can feel emotionally challenging, even when the medical risk is low. For you, it is normal to feel anxious before tests or to worry that new sensations might mean the cancer has changed.

If this anxiety begins to affect your sleep, work, relationships or overall quality of life, it is important to speak with your care team. They can offer support and help you put your concerns into context.

You can ask your clinical team to review your surveillance plan at any time. Decisions about moving from surveillance to active treatment should be made together with your team, taking into account your preferences, health and how you are coping emotionally.

Why Keeping Every Follow-up Appointment Matters

Active surveillance works best when your tests and reviews happen as planned. For you, regular PSA tests, scans and appointments allow your team to track patterns over time and spot any meaningful changes early.

Missing appointments can create gaps in this pattern, making it harder to assess whether your cancer is stable or changing. Repeatedly missing or delaying tests can make PSA and imaging trends more difficult to interpret and may delay necessary reassessment.

It helps to know who is responsible for arranging each test and how you will receive your results. If something is delayed or unclear, contact your clinic rather than assuming that no news means everything is fine.

What Long-Term Research Tells You

The UK ProtecT trial followed 1,643 men with localised prostate cancer who were assigned to active monitoring, surgery or radiotherapy. After a median follow-up of 15 years, prostate cancer mortality was low in all three groups and there was no statistically significant difference between them.

More than one-third of the participants were classified as having intermediate-risk or high-risk disease when contemporary risk definitions were applied. The results should therefore not be interpreted as applying only to men with low-risk or slow-growing prostate cancer.

Prostate cancer caused death in 3.1% of men assigned to active monitoring, 2.2% assigned to surgery and 2.9% assigned to radiotherapy. However, metastases developed more often in the active-monitoring group, affecting 9.4%, compared with 4.7% after surgery and 5.0% after radiotherapy. Clinical progression and the need for long-term hormone therapy were also more common with active monitoring.

These findings do not mean that monitoring is suitable for every localised prostate cancer or that modern active surveillance has exactly the same outcomes. The trial used a mainly PSA-led active-monitoring approach that began before routine multiparametric MRI and contemporary risk-stratified surveillance became established. Its findings should therefore be considered alongside a person’s current CPG risk group and the monitoring programme offered today.

Frequently Asked Questions

1. Can slow-growing prostate cancer become aggressive?
Yes, slow-growing prostate cancer can show biological progression, although progression is not inevitable. In some cases, later tests reveal higher-grade cancer that was already present but was not detected during the original assessment.

2. What does slow-growing prostate cancer mean?
 It means your cancer is expected to grow slowly and is less likely to spread quickly. In many cases, it may not affect your life expectancy or require immediate treatment. This is why active surveillance is often recommended instead of surgery or radiotherapy straight away. However, it still requires careful monitoring over time.

3. How is prostate cancer monitored during active surveillance?
Your doctor will usually monitor your cancer with regular PSA tests, MRI scans and check-ups. In some cases, repeat biopsies are also needed to reassess the cancer more directly. These tests help build a clear picture of whether your cancer is stable or changing. Monitoring schedules may vary depending on your individual risk.

4. Does a rising PSA mean prostate cancer is becoming aggressive?
Not always, as PSA levels can rise for several non-cancer reasons such as inflammation or prostate enlargement. Your doctor looks at how PSA changes over time rather than relying on a single result. Patterns like a steady increase may prompt further investigation. Additional tests such as MRI or biopsy may be recommended if there is concern.

5. What are the signs of prostate cancer progression?
Signs of progression can include a higher Grade Group on biopsy or more cancer found in samples. Changes on MRI, such as a growing or more suspicious lesion, may also be important. A concerning PSA pattern may lead to further assessment, but PSA results alone cannot confirm that the cancer has become more aggressive.

6. How long can active surveillance continue?
Many men remain on active surveillance for several years, and some may never need active treatment. Surveillance can continue while the cancer remains suitable for monitoring, you are able to attend follow-up assessments and the approach remains acceptable to you.

7. When might treatment become necessary?
Treatment may be recommended if there is clear evidence that your cancer is becoming more active. This could include changes in biopsy results, MRI findings or PSA trends. The aim is to identify clinically important progression while treatment with curative intent remains possible. Your personal preferences and overall health are also important in this decision.

8. Are symptoms a reliable sign of progression?
No, early prostate cancer often does not cause symptoms, even if it is changing. Waiting for symptoms is not a reliable way to detect progression. Monitoring tests are designed to identify changes much earlier. You should still report any new or concerning symptoms to your doctor.

9. Can lifestyle changes prevent progression?
Healthy habits such as regular exercise, a balanced diet and not smoking can support your overall health. However, they cannot guarantee that your cancer will not progress. It is important not to rely on lifestyle changes alone instead of medical monitoring. Staying engaged with your surveillance plan remains essential.

10. How can you feel more confident during active surveillance?
Understanding your diagnosis, attending your follow-up appointments and discussing your results with your clinical team may help you feel more informed. Knowing which changes your team is monitoring and taking part in treatment discussions may also reduce uncertainty and support informed decision-making.

Final Thoughts: Monitoring Slow-Growing Prostate Cancer With Confidence

Slow-growing prostate cancer often remains stable for many years, and in many cases may never cause harm. However, some cancers show clinically important changes over time, which is why structured monitoring through active surveillance is important. Regular PSA testing, MRI scans and clinical reviews may help identify meaningful changes while treatment with curative intent remains possible.

Understanding your individual risk, staying engaged with follow-up appointments and discussing any concerns with your specialist can help you feel more confident in your care plan. If your situation changes, your team can reassess which treatment options remain clinically suitable and discuss how they align with your needs and priorities.

If you are considering prostate cancer surgery in London and would like specialist advice, you can contact us to discuss your options and arrange a consultation tailored to your individual needs.

References

1. Cambridge University Hospitals NHS Foundation Trust (2023) Active surveillance for Cambridge prognostic group 1 and 2 CPG1 and CPG2 early prostate cancer. Approved 16 February 2023. Available at: https://www.cuh.nhs.uk/patient-information/active-surveillance-for-cambridge-prognostic-group-1-and-2-cpg1-and-cpg2-early-prostate-cancer/
2. Dovey, Z., Horowitz, A. and Waingankar, N. (2023) ‘The influence of lifestyle changes diet, exercise and stress reduction on prostate cancer tumour biology and patient outcomes: a systematic review’, BJUI Compass, 4(4), pp. 385–416. Available at: https://pubmed.ncbi.nlm.nih.gov/37334023/
3. Gnanapragasam, V.J., Keates, A., Lophatananon, A. and Thankapannair, V. (2025) ‘The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer’, BJU International, 135(5), pp. 851–859. Available at: https://pubmed.ncbi.nlm.nih.gov/39888260/
4. Hamdy, F.C. et al. (2023) ‘Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer’, The New England Journal of Medicine, 388(17), pp. 1547–1558. Available at: https://pubmed.ncbi.nlm.nih.gov/36912538/
5. Mac Curtain, B.M., Daly, K., Calpin, G. et al. (2025) ‘Reclassification of prostate cancer on first confirmatory prostate biopsy in men under active surveillance: a systematic review and meta-analysis’, Central European Journal of Urology, 78, pp. 125–136. Available at: https://pubmed.ncbi.nlm.nih.gov/40873874/
6. National Institute for Health and Care Excellence (2012) Focal therapy using cryoablation for localised prostate cancer. HealthTech guidance HTG284. Available at: https://www.nice.org.uk/guidance/htg284
7. National Institute for Health and Care Excellence (2019) Prostate cancer: diagnosis and management. NICE guideline NG131. Last updated 15 December 2021 and last reviewed 13 August 2025. Available at: https://www.nice.org.uk/guidance/ng131
8. National Institute for Health and Care Excellence (2021) Shared decision making. NICE guideline NG197. Available at: https://www.nice.org.uk/guidance/ng197
9. National Institute for Health and Care Excellence (2023) Focal therapy using high-intensity focused ultrasound for localised prostate cancer. HealthTech guidance HTG667. Available at: https://www.nice.org.uk/guidance/htg667
10. NHS (2025) Symptoms of prostate cancer. Last reviewed 31 July 2025. Available at: https://www.nhs.uk/conditions/prostate-cancer/symptoms/
11. NHS (2025) Treatment for prostate cancer. Last reviewed 31 July 2025. Available at: https://www.nhs.uk/conditions/prostate-cancer/treatment/
12. Schoots, I.G. et al. (2018) ‘Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis’, BJU International, 122(6), pp. 946–958. Available at: https://pubmed.ncbi.nlm.nih.gov/29679430/
13. National Institute for Health and Care Excellence (2023) Spinal metastases and metastatic spinal cord compression. NICE guideline NG234. Available at: https://www.nice.org.uk/guidance/ng234
14. NHS England Genomics Education Programme (2025) Presentation: Patient with a family history of prostate cancer. Last reviewed 24 March 2025. Available at: https://www.genomicseducation.hee.nhs.uk/genotes/in-the-clinic/patient-with-a-family-history-of-prostate-cancer/
15. Nyberg, T. et al. (2020) ‘Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study’, European Urology, 77(1), pp. 24–35. Available at: https://pubmed.ncbi.nlm.nih.gov/31495749/